NCT07088484View on ClinicalTrials.gov

Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma

Not yet recruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

September 1, 2027

Study Completion Date

September 1, 2027

Conditions
Recurrent Nasopharyngeal Carcinoma
Interventions
DRUG

ICI-chemotherapy and LIMT

gemcitabine, docetaxel, paclitaxel, cisplatin, platinum, capecitabine, S1; Tislelizumab.

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV

NCT07088484 - Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter